Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide with the fastest rising incidence and mortality in the United States.
Our lab is interested in identifying disease-acquired functions of RNA binding proteins (RBPs), and in parallel, exploit such mechanisms as actionable biomarkers or drug targets to improve diagnosis for PLC patients.
Our lab utilizes bioinformatics and bench science spanning from functional genomics, translational science, molecular epidemiology, RNA biology, cancer biology, and animal models to investigate the oncogenic roles of RBPs in PLC.